Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 82

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 82
---
 assets$1 $12 $4 $36 Total finance lease cost1 12 4 36 Operating lease cost205 119 612 330 Short-term lease cost32 59 127 177 Variable lease cost10 26 36 39 Less: sublease income(27)(50)(105)(128)Total lease costs$221 $166 $674 $454 

25

Supplemental cash flow information related to leases was as follows (in thousands):Nine months ended September 30,20252024Cash paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases$688 $405 Operating cash flows from short-term leases127 177 Operating cash flows from variable lease costs36 39 Right-of-use assets obtained in exchange for lease liabilities:Operating leases$1,115 $419 Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate):September 30,2025December 31,2024Finance LeasesProperty and equipment, at cost$1,031 $1,031 Less: accumulated depreciation and amortization(1,026)(1,023)Property and equipment, net$5 $8 Operating LeasesOperating lease right-of-use assets$1,337 $657 Current portion of operating lease liabilities$441 $420 Operating lease liabilities, less current portion966 372 Total operating lease liabilities$1,407 $792 Weighted Average Remaining Lease TermOperating leases (in years)33Weighted Average Discount RateOperating leases12.9%9.9%Maturities of lease liabilities were as follows (in thousands):Year Ended December 31,OperatingLeases2025 (excluding the nine months ended September 30, 2025)$172 2026552 2027542 2028393 202939 Total lease payments1,698 Less: future interest expense(291)Lease liabilities$1,407 

26

L.    Goodwill & Intangible AssetsThe Company's goodwill balance was $4.7 million as of September 30, 2025, and December 31, 2024. As of September 30, 2025, and December 31, 2024, non-amortizable intangible assets include $2.0 million related to in-process research and development associated with the